Focus on head and neck cancer

21 October 2019

Q: What is Head and Neck Cancer?

A: Head and Neck Cancer (HNC) is a grouping of cancers involving the larynx, pharynx, oral cavity, sinonasal area, thyroid and salivary glands. HNC is not a common cancer, with 12,000 new cases diagnosed per year in the UK; which is a similar incidence to renal cancer. However, the incidence of some HNC types are rapidly increasing; especially thyroid (75% increase in last 10 years) and oropharyngeal (50% increase in last 20 years).

 

Q: What causes Head and Neck cancer?

A: Most cases of HNC are squamous cell carcinomas, and are caused by tobacco smoking and alcohol, and occur in more deprived populations. However, 50% of oropharyngeal cancers we treat now are related to the Human Papilloma Virus. These patients are typically non-smokers and more affluent.

 

Q: How is it diagnosed?

A: Patients will often present with symptoms from the primary, such as a unilateral sore throat or hoarse voice, or as a neck lump, from cervical lymph node metastasis. A tissue biopsy, or fine needle aspiration, is required from the neck or primary site to confirm a cancer diagnosis. CT and/or MRI scans are also required for staging. One-stop clinics combine many of these tests into one consultation.

 

Q: How is it treated?

A: All cancer patients should be discussed in a Multi-Disciplinary Team setting. Treatment modalities include surgery, radiotherapy and chemotherapy. Patients with advanced disease often require multi-modality treatment. Surgical advances allow minimal access techniques using trans-oral lasers and robotic technology. Refinements in radiotherapy delivery with Intensity Modulated Radiotherapy (IMRT) help to reduce side effects of conventional radiotherapy. Immunotherapy is a promising new therapeutic modality for metastatic and recurrent disease.

 

Jonathan Hughes runs a One-Stop Neck lump clinic and general ENT clinic on Saturday mornings at Spire Bushey. 

Event Booking Form

119924

Marketing Information

Spire would like to provide you with marketing information about products and services offered by Spire and by selected third-party partners. If you do not consent for us to process your personal data for marketing activities, we will still be able to contact you about your enquiry.

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.